Cover Image
Market Research Report

Transmucosal Drug Delivery - Medical Devices Pipeline Assessment, 2018

Published by GlobalData Product code 654786
Published Content info 194 Pages
Immediate Delivery Available
Price
Back to Top
Transmucosal Drug Delivery - Medical Devices Pipeline Assessment, 2018
Published: June 14, 2018 Content info: 194 Pages
Description

GlobalData's Medical Devices sector report, "Transmucosal Drug Delivery - Medical Devices Pipeline Assessment, 2018" provides an overview of Transmucosal Drug Delivery currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Transmucosal Drug Delivery pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Transmucosal Drug Delivery under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Transmucosal Drug Delivery and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Transmucosal Drug Delivery under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date
Table of Contents
Product Code: GDME0610EPD

Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 7
  • 1.2 List of Figures 11

2 Introduction 12

  • 2.1 Transmucosal Drug Delivery Overview 12

3 Products under Development 13

  • 3.1 Transmucosal Drug Delivery - Pipeline Products by Stage of Development 13
  • 3.2 Transmucosal Drug Delivery - Pipeline Products by Segment 14
  • 3.3 Transmucosal Drug Delivery - Pipeline Products by Territory 15
  • 3.4 Transmucosal Drug Delivery - Pipeline Products by Regulatory Path 16
  • 3.5 Transmucosal Drug Delivery - Pipeline Products by Estimated Approval Date 17
  • 3.6 Transmucosal Drug Delivery - Ongoing Clinical Trials 18

4 Transmucosal Drug Delivery - Pipeline Products under Development by Companies 19

  • 4.1 Transmucosal Drug Delivery Companies - Pipeline Products by Stage of Development 19
  • 4.2 Transmucosal Drug Delivery - Pipeline Products by Stage of Development 21

5 Transmucosal Drug Delivery Companies and Product Overview 23

  • 5.1 AcelRx Pharmaceuticals Inc Company Overview 23
  • 5.2 Albert Einstein College of Medicine Company Overview 29
  • 5.3 Allergan Plc Company Overview 30
  • 5.4 Amphastar Pharmaceuticals Inc Company Overview 31
  • 5.5 BeFree! Company Overview 32
  • 5.6 Bespak Europe Ltd Company Overview 33
  • 5.7 Biorings LLC Company Overview 35
  • 5.8 BMG Pharma srl Company Overview 36
  • 5.9 Columbia University Company Overview 38
  • 5.10 Combinent BioMedical Systems Inc Company Overview 39
  • 5.11 Conrad Company Overview 40
  • 5.12 Corium International Inc Company Overview 42
  • 5.13 Dare Bioscience Inc Company Overview 44
  • 5.14 Dermtreat ApS Company Overview 49
  • 5.15 Emergent BioSolutions Inc Company Overview 52
  • 5.16 Evestra Inc Company Overview 53
  • 5.17 Evofem Biosciences Inc Company Overview 56
  • 5.18 Ferring Pharmaceuticals A/S Company Overview 57
  • 5.19 Ghent University Company Overview 59
  • 5.20 Karessa Pharma AB Company Overview 60
  • 5.21 Kytogenics Pharmaceuticals Inc Company Overview 62
  • 5.22 Laboratoire HRA Pharma SAS Company Overview 63
  • 5.23 Laboratorios Andromaco Company Overview 64
  • 5.24 McNeil AB Company Overview 65
  • 5.25 Merck & Co Inc Company Overview 66
  • 5.26 Merck Serono SA Company Overview 67
  • 5.27 Merck Sharp & Dohme Ltd Company Overview 69
  • 5.28 Mercy Research and Development Company Overview 70
  • 5.29 Mithra Pharmaceuticals SA Company Overview 71
  • 5.30 Mystic Pharmaceuticals Inc Company Overview 72
  • 5.31 Nanosys Inc Company Overview 74
  • 5.32 NorInvent AB Company Overview 75
  • 5.33 Novus Therapeutics Inc Company Overview 76
  • 5.34 Oak Crest Institute of Science Company Overview 77
  • 5.35 Opiant Pharmaceuticals Inc Company Overview 78
  • 5.36 OptiNose AS Company Overview 82
  • 5.37 RDD Pharma Ltd Company Overview 84
  • 5.38 Rhinomed Ltd Company Overview 87
  • 5.39 Shin Nippon Biomedical Laboratories Ltd Company Overview 88
  • 5.40 Sonoma Pharmaceuticals Inc Company Overview 89
  • 5.41 Texas Tech University Company Overview 90
  • 5.42 The Hong Kong University of Science and Technology Company Overview 91
  • 5.43 Therakind Ltd Company Overview 92
  • 5.44 UCB SA Company Overview 93
  • 5.45 University of North Carolina at Chapel Hill Company Overview 94
  • 5.46 University of South Florida Company Overview 95
  • 5.47 University of Texas at Austin Company Overview 96
  • 5.48 University of the Witwatersrand Company Overview 97
  • 5.49 University of Washington Company Overview 98
  • 5.50 Yale School of Medicine Company Overview 99

6 Transmucosal Drug Delivery- Recent Developments 100

  • 6.1 Jun 06, 2018: Dare Bioscience Expands Leadership Team, Appointing David Friend, Ph.D. to Chief Scientific Officer 100
  • 6.2 Jun 04, 2018: Dare Bioscience Appoints Mary Jarosz To Global Head Of Regulatory Affairs 100
  • 6.3 Jun 04, 2018: RDD Pharma Names Dr. Mark Sirgo As Chairman Of The Board Of Directors 101
  • 6.4 May 29, 2018: Egalet Announces Large Regional Plan to Cover SPRIX Nasal Spray 101
  • 6.5 May 29, 2018: ADAPT Pharma Launches New Online Platform for NARCAN 102
  • 6.6 May 28, 2018: Update on Mithra and Mayne Pharma's Vaginal Contraceptive Ring Opportunity 102
  • 6.7 May 24, 2018: AcelRx announces FDA acceptance of NDA for DSUVIA 103
  • 6.8 May 21, 2018: Summit Medical Group Research Aids in FDA Approval of Drug for Nasal Polyps 104
  • 6.9 May 18, 2018: Avadel to Present Late-Breaker Data and Product Theater Forum at the 2018 American Urological Association Annual Meeting 104
  • 6.10 May 15, 2018: Dare Bioscience Announces Trial Initiation for Ovaprene Non-Hormonal Monthly Contraceptive Candidate 106
  • 6.11 May 14, 2018: Corium Announces Second Quarter Fiscal 2018 Financial Results 106
  • 6.12 May 10, 2018: BioDelivery Sciences Reports Positive First Quarter 2018 Financial Results and Provides Corporate Update 108
  • 6.13 May 09, 2018: Quebec Government makes NARCAN Nasal Spray free to anyone 14 years or older through Free naloxone program 109
  • 6.14 May 09, 2018: AcelRx resubmits New Drug Application for DSUVIA 110
  • 6.15 May 09, 2018: AcelRx Pharmaceuticals Reports First Quarter 2018 Financial Results 111
  • 6.16 May 08, 2018: Dare Bioscience Expands Leadership Team, Appointing John Fair to Chief Business Officer 111
  • 6.17 May 08, 2018: Sonoma Pharmaceuticals Names Marc Umscheid Chief Operating Officer 112
  • 6.18 May 07, 2018: Optinose Provides Update on XHANCE 112
  • 6.19 May 07, 2018: BioDelivery Sciences Names Herm Cukier As Chief Executive Officer 112
  • 6.20 May 01, 2018: Avadel Launches NOCTIVA, the First and Only FDA-Approved Treatment for Nocturia Due to Nocturnal Polyuria 113
  • 6.21 Apr 30, 2018: AcelRx Pharmaceuticals Reports Publication Analyzing Errors Associated with Existing IV Patient-Controlled Analgesia Systems 114
  • 6.22 Apr 30, 2018: A Retrospective Analysis & Literature Review Published in Pain Management on the Pharmacokinetic Properties of Naloxone Approved for Community Use Highlights Bioequivalence of Dose & Usability 114
  • 6.23 Apr 30, 2018: Dare Bioscience announces funding award to further the development of Ovaprene from the National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 115
  • 6.24 Apr 26, 2018: Adapt Pharma donates 20,000 doses of NARCAN (naloxone HCl) Nasal Spray to the National Council for Behavioral Health and its Residential Treatment Member Organizations 116
  • 6.25 Apr 26, 2018: Consort Medical: Director Declaration 117
  • 6.26 Apr 25, 2018: Dermtreat Appoints Nishan de Silva, M.D., as CEO; Establishes North American Headquarters in San Diego 117
  • 6.27 Apr 25, 2018: A Retrospective Literature Review Published in Pain Management on Prescribing Naloxone for Opioid Overdose Intervention Highlights Opportunities to Expand Community Access to Help Reduce Fatalities 118
  • 6.28 Apr 16, 2018: AcelRx Announces Completion of the Human Factors Study for DSUVIA and Confirms Plans to Resubmit NDA in Q2 2018 119
  • 6.29 Apr 11, 2018: Jessica Grossman Joins Dare Bioscience Board of Directors 119
  • 6.30 Apr 09, 2018: Adapt Pharma Welcomes Canadian & Ontario Governments Programs Providing NARCAN (naloxone HCl) Nasal Spray Free of Charge to NIHB Clients and All Ontarians through Pharmacies 119
  • 6.31 Apr 05, 2018: ADAPT Pharma Welcomes Surgeon General Naloxone Advisory 121
  • 6.32 Apr 05, 2018: Naloxone Nasal Spray now available to First Nations and Inuit through Non-Insured Health Benefits program 122
  • 6.33 Apr 05, 2018: CVS Health Expands Efforts to Educate Patients about Naloxone 122
  • 6.34 Apr 04, 2018: Cardinal Health Begins Donation of Over 80,000 Doses of Life-Saving Narcan for Distribution to Law Enforcement and First Responders in Appalachia 123
  • 6.35 Apr 02, 2018: Intersect ENT Announces Launch of SINUVA Sinus Implant, a New In-Office Treatment Option for Recurrent Nasal Polyps 124
  • 6.36 Mar 27, 2018: AcelRx Pharmaceuticals Names John Saia As General Counsel 125
  • 6.37 Mar 20, 2018: Mithra And Mayne Pharma Vaginal Contraceptive Ring Accepted For Filing By FDA 125
  • 6.38 Mar 19, 2018: ADAPT Pharma Expands Program Offering Free NARCAN (naloxone HCl) Nasal Spray to Eligible Schools and Universities 126
  • 6.39 Mar 16, 2018: Intention to grant for the XtriG-patent in Europe 127
  • 6.40 Mar 16, 2018: BioDelivery Sciences Announces Fourth Quarter and Full-Year 2017 Financial Results 127
  • 6.41 Mar 13, 2018: Injectable Medication Shortage is Affecting Terminally Ill Patients 129
  • 6.42 Mar 08, 2018: Notice of Allowance for XtriG patent in the USA 130
  • 6.43 Mar 08, 2018: AcelRx Pharmaceuticals Reports Fourth Quarter 2017 Financial Results 130
  • 6.44 Mar 07, 2018: Ontario Government takes significant action to address opioid crisis; NARCAN Nasal Spray to be made available to all Ontarians free of charge through pharmacies 131
  • 6.45 Mar 06, 2018: High uptake and use of vaginal ring for HIV prevention observed in open-label study 132
  • 6.46 Feb 27, 2018: Optinose to Highlight Data at the 2018 AAAAI/WAO Joint Congress 134
  • 6.47 Feb 22, 2018: Teleflex Highlights LMA Gastro Airway Study, Which Shows Efficacy for Use in Upper Gastrointestinal Endoscopy 135
  • 6.48 Feb 08, 2018: AptarGroup and Adapt Pharma Donate NARCAN Nasal Spray to Opioid Crisis Coalitions in Illinois 135
  • 6.49 Feb 08, 2018: Opiant Pharmaceuticals to Record Approximately $11.7 Million in Royalty and Milestone Payments Related to 2017 Sales of NARCAN Nasal Spray for Opioid Overdose 137
  • 6.50 Feb 08, 2018: Opiant Pharmaceuticals to Record Approximately $11.7 Million in Royalty and Milestone Payments Related to 2017 Sales of NARCAN Nasal Spray for Opioid Overdose 137
  • 6.51 Feb 08, 2018: Corium Reports First Quarter Fiscal 2018 Financial Results and Corporate Highlights 137
  • 6.52 Feb 07, 2018: Sonoma Pharmaceuticals Reports Record Total Revenue of $4.8 million for Third Quarter FY 2018 with Year over Year Product Revenue Growth of 46% 139
  • 6.53 Feb 06, 2018: BioDelivery Sciences Announces BELBUCA Patent Litigation Settlement Agreement with Teva 140
  • 6.54 Jan 22, 2018: Intersect ENT Announces Publication of Randomized Pivotal Study of the SINUVA Sinus Implant, a New In-Office Treatment Option for Recurrent Nasal Polyps 140
  • 6.55 Jan 11, 2018: Dermtreat Submits IND And CTA For Phase 2b Study 142
  • 6.56 Jan 04, 2018: RDD Pharma Completes Enrollment in European Phase 3 Clinical Trial for Chronic Anal Fissure 143

7 Appendix 190

  • 7.1 Methodology 190
  • 7.2 About GlobalData 193
  • 7.3 Contact Us 193
  • 7.4 Disclaimer 193

List of Tables

  • Table 1: Transmucosal Drug Delivery - Pipeline Products by Stage of Development 14
  • Table 2: Transmucosal Drug Delivery - Pipeline Products by Segment 15
  • Table 3: Transmucosal Drug Delivery - Pipeline Products by Territory 16
  • Table 4: Transmucosal Drug Delivery - Pipeline Products by Regulatory Path 17
  • Table 5: Transmucosal Drug Delivery - Pipeline Products by Estimated Approval Date 18
  • Table 6: Transmucosal Drug Delivery - Ongoing Clinical Trials 19
  • Table 7: Transmucosal Drug Delivery Companies - Pipeline Products by Stage of Development 20
  • Table 8: Transmucosal Drug Delivery - Pipeline Products by Stage of Development 22
  • Table 9: AcelRx Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 24
  • Table 10: ARX-02 Sufentanil NanoTab BTP Management System - Product Status 24
  • Table 11: ARX-02 Sufentanil NanoTab BTP Management System - Product Description 25
  • Table 12: ARX-03 Sufentanil/Trazolam NanoTab - Product Status 25
  • Table 13: ARX-03 Sufentanil/Trazolam NanoTab - Product Description 25
  • Table 14: DSUVIA Single-Dose Applicator - Product Status 26
  • Table 15: DSUVIA Single-Dose Applicator - Product Description 26
  • Table 16: ZALVISO - Product Status 26
  • Table 17: ZALVISO - Product Description 27
  • Table 18: AcelRx Pharmaceuticals Inc - Ongoing Clinical Trials Overview 28
  • Table 19: ZALVISO - Treatment of Acute Post-operative Pain in Patients Undergoing Laparoscopic Colon Resections 29
  • Table 20: ZALVISO - Usability and Satisfaction Evaluation of Sufentanil Sublingual Patient-Controlled Analgesia After Elective Surgery With Moderate-to-Severe Postoperative Pain 29
  • Table 21: Albert Einstein College of Medicine Pipeline Products & Ongoing Clinical Trials Overview 30
  • Table 22: Drug-Impregnated Intravaginal Ring - Product Status 30
  • Table 23: Drug-Impregnated Intravaginal Ring - Product Description 30
  • Table 24: Allergan Plc Pipeline Products & Ongoing Clinical Trials Overview 31
  • Table 25: Vaginal Ring Contraceptive - Product Status 31
  • Table 26: Vaginal Ring Contraceptive - Product Description 31
  • Table 27: Amphastar Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 32
  • Table 28: Intranasal Naloxone Spray - Product Status 32
  • Table 29: Intranasal Naloxone Spray - Product Description 32
  • Table 30: BeFree! Pipeline Products & Ongoing Clinical Trials Overview 33
  • Table 31: Vaginal Drug Delivery System - Product Status 33
  • Table 32: Vaginal Drug Delivery System - Product Description 33
  • Table 33: Bespak Europe Ltd Pipeline Products & Ongoing Clinical Trials Overview 34
  • Table 34: NAS010 - Product Status 34
  • Table 35: NAS010 - Product Description 34
  • Table 36: NAS020 - Unidose Nasal Drug Delivery Device - Product Status 35
  • Table 37: NAS020 - Unidose Nasal Drug Delivery Device - Product Description 35
  • Table 38: NAS030 Nasal Device - Product Status 35
  • Table 39: NAS030 Nasal Device - Product Description 35
  • Table 40: Biorings LLC Pipeline Products & Ongoing Clinical Trials Overview 36
  • Table 41: Vaginal Ring - Product Status 36
  • Table 42: Vaginal Ring - Product Description 36
  • Table 43: BMG Pharma srl Pipeline Products & Ongoing Clinical Trials Overview 37
  • Table 44: Isysin Hyper - Product Status 37
  • Table 45: Isysin Hyper - Product Description 37
  • Table 46: Isysin Iso - Product Status 37
  • Table 47: Isysin Iso - Product Description 38
  • Table 48: Columbia University Pipeline Products & Ongoing Clinical Trials Overview 39
  • Table 49: Focused Ultrasound - Intranasal Drug Delivery - Product Status 39
  • Table 50: Focused Ultrasound - Intranasal Drug Delivery - Product Description 39
  • Table 51: Combinent BioMedical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 40
  • Table 52: Multi-Segmented Vaginal Ring - Product Status 40
  • Table 53: Multi-Segmented Vaginal Ring - Product Description 40
  • Table 54: Conrad Pipeline Products & Ongoing Clinical Trials Overview 41
  • Table 55: Triple Protection Vaginal Ring - Product Status 41
  • Table 56: Triple Protection Vaginal Ring - Product Description 41
  • Table 57: Vaginal Ring - HIV Protection - Product Status 42
  • Table 58: Vaginal Ring - HIV Protection - Product Description 42
  • Table 59: Corium International Inc Pipeline Products & Ongoing Clinical Trials Overview 43
  • Table 60: Rapidly Dissolving Film - Product Status 43
  • Table 61: Rapidly Dissolving Film - Product Description 43
  • Table 62: Solid State Film - Product Status 44
  • Table 63: Solid State Film - Product Description 44
  • Table 64: Dare Bioscience Inc Pipeline Products & Ongoing Clinical Trials Overview 45
  • Table 65: Intravaginal Ring - Product Status 45
  • Table 66: Intravaginal Ring - Product Description 46
  • Table 67: Ovaprene - Product Status 46
  • Table 68: Ovaprene - Product Description 46
  • Table 69: Dare Bioscience Inc - Ongoing Clinical Trials Overview 47
  • Table 70: Ovaprene - Post-coital Test (PCT) Clinical Study to Evaluate Safety and Efficacy of Ovaprene Non-hormonal Monthly Contraceptive Candidate 48
  • Table 71: Intravaginal Ring - A Phase I Clinical Study of JNP-0201 49
  • Table 72: Intravaginal Ring - A Phase I Clinical Study of JNP-0301 49
  • Table 73: Intravaginal Ring - Phase IIa Study of JNP-0101 49
  • Table 74: Intravaginal Ring - Phase III Study of JNP-0101 49
  • Table 75: Dermtreat ApS Pipeline Products & Ongoing Clinical Trials Overview 50
  • Table 76: Rivelin Clobetasol Patch - Product Status 50
  • Table 77: Rivelin Clobetasol Patch - Product Description 50
  • Table 78: Dermtreat ApS - Ongoing Clinical Trials Overview 51
  • Table 79: Rivelin Clobetasol Patch - Phase IIb Clinical Study of Rivelin Clobetasol Patch in Treatment of Oral Lichen Planus (OLP) 52
  • Table 80: Emergent BioSolutions Inc Pipeline Products & Ongoing Clinical Trials Overview 53
  • Table 81: Intranasal SIAN Device - Product Status 53
  • Table 82: Intranasal SIAN Device - Product Description 53
  • Table 83: Evestra Inc Pipeline Products & Ongoing Clinical Trials Overview 54
  • Table 84: EVE112 - Vaginal Ring - Product Status 54
  • Table 85: EVE112 - Vaginal Ring - Product Description 54
  • Table 86: EVE116 - Product Status 55
  • Table 87: EVE116 - Product Description 55
  • Table 88: Progestin Vaginal Ring - Product Status 55
  • Table 89: Progestin Vaginal Ring - Product Description 56
  • Table 90: Vaginal Ring For Preterm Labor - Product Status 56
  • Table 91: Vaginal Ring For Preterm Labor - Product Description 56
  • Table 92: Evofem Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 57
  • Table 93: Nestorone/Ethinyl estradiol (NES/EE) Contraceptive Vaginal Ring (CVR) - Product Status 57
  • Table 94: Nestorone/Ethinyl estradiol (NES/EE) Contraceptive Vaginal Ring (CVR) - Product Description 57
  • Table 95: Ferring Pharmaceuticals A/S Pipeline Products & Ongoing Clinical Trials Overview 58
  • Table 96: C-Vad Vaginal Insert - Product Status 58
  • Table 97: C-Vad Vaginal Insert - Product Description 58
  • Table 98: Premis Vaginal Insert - Product Status 59
  • Table 99: Premis Vaginal Insert - Product Description 59
  • Table 100: Ghent University Pipeline Products & Ongoing Clinical Trials Overview 60
  • Table 101: Controlled-Release System - Intra-Vaginal Delivery - Product Status 60
  • Table 102: Controlled-Release System - Intra-Vaginal Delivery - Product Description 60
  • Table 103: Karessa Pharma AB Pipeline Products & Ongoing Clinical Trials Overview 61
  • Table 104: K-01 - Product Status 61
  • Table 105: K-01 - Product Description 61
  • Table 106: K-02 - Product Status 62

List of Figures

  • Figure 1: Transmucosal Drug Delivery - Pipeline Products by Stage of Development 14
  • Figure 2: Transmucosal Drug Delivery - Pipeline Products by Segment 15
  • Figure 3: Transmucosal Drug Delivery - Pipeline Products by Territory 16
  • Figure 4: Transmucosal Drug Delivery - Pipeline Products by Regulatory Path 17
  • Figure 5: Transmucosal Drug Delivery - Pipeline Products by Estimated Approval Date 18
  • Figure 6: Transmucosal Drug Delivery - Ongoing Clinical Trials 19
Back to Top